论文部分内容阅读
目的 探讨参附注射液治疗AMI合并HF的临床疗效。方法 4 8例AMI合并HF患者 ,在综合治疗的基础上随机分为治疗组 (参附注射液 4 0～ 6 0ml加入 5 %GS 2 5 0ml静滴 ,每日 1次 )与对照组 (多巴酚丁胺 4 0mg加入 5 %GS 2 5 0ml静滴每日 1次 )各 2 4例 ,以 10d为 1个疗程。观察两组治疗对心功能、症状、体征的影响及不良反应。结果 第 1疗程后治疗组总有效率 75 0 % ,第 2疗程为 91 3% ;而对照组分别为 4 5 8%与 6 3 6 % (P <0 0 5和P <0 0 1)。第 2疗程后治疗组HR及LVEF分别较对照组明显下降及升高 (P <0 0 1和P <0 0 5 ) ,且未见不良反应。结论 参附注射液治疗AMI合并HF安全有效 ,并随着疗程的延长可进一步改善心功能 ,达到标本兼治
Objective To investigate the clinical efficacy of Shenfu injection in the treatment of AMI combined with HF. Methods Forty-eight patients with AMI complicated with HF were randomly divided into treatment group (Shenfu injection 40 ~ 60ml plus 5% GS 250 ml once daily) and control group Butabutin 4 0mg added 5% GS 250ml intravenously once daily) 24 cases each to 10d for a course of treatment. The effects of two treatments on cardiac function, symptoms and signs and adverse reactions were observed. Results After the first course of treatment, the total effective rate was 75 0% in the treatment group and 91 3% in the second course, while it was 45 58% and 63 6% in the control group (P 0 05 and P 0 01, respectively). After the second course of treatment, the HR and LVEF in the treatment group were significantly lower and higher than those in the control group (P <0.01 and P <0.05), and no adverse reactions were observed. Conclusion Shenfu injection for the treatment of AMI combined with HF safe and effective, and as the course of treatment can further improve cardiac function, to achieve both the symptoms